Overview

Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Gliomas are the most common malignant tumors of the central nervous system and are highly invasive. Gliomas account for one-third of central nervous system tumors in adults and children. Interstitial astrocytomas and glioblastomas are also called high-grade gliomas, accounting for 77.5% of all gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
WuHui
Treatments:
Apatinib
Temozolomide